doi:https://doi.org/

References:

Nissen S.E., Yeomans N.D., Solomon D.H., et al. PRECISION Trial Investigators. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med 2016;375:2519—2529.
Debray T.P., Moons K.G., van Valkenhoef G., et al. GetReal Methods Review Group. Get real in individual participant data (IPD) meta-analysis: a review of the methodology. Res Synth Methods 2015;6:293—309.
Warren F.C., Abrams K.R., Golder S., Sutton A.J. Systematic review of methods used in meta-analyses where a primary outcome is an adverse or unintended event. BMC Med Res Methodol 2012;12:64.
Trelle S., Reichenbach S., Wandel S., et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011;342:c7086.
Bhala N., Emberson J., Merhi A., et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013;382:769—779.
Steering Committee of the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT). Statement for communication to the FDA Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee. 18 February 2005. Available at: https://jhuccs1.us/adapt/pdf%20documents/FDA%20ADAPT%20 STATEMENT_web%20posting.pdf. Last accessed December 13, 2015.
Varas-Lorenzo C., Riera-Guardia N., Calingaert B., et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 2013;22:559—570.
Bueno H., Bardají A., Patrignani P., et al. Spanish Case-Control Study to Assess NSAID-Associated ACS Risk Investigators. Use of non-steroidal antiinflammatory drugs and type-specific risk of acute coronary syndrome. Am J Cardiol 2010;105:1102—1106.
Kimmel S.E., Berlin J.A., Reilly M., et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005;142:157—164.
Mamdani M., Rochon P., Juurlink D.N., et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003;163:481—486.
Graham D.J., Campen D., Hui R., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005;365:475—481.
van der Linden M.W., van der Bij S., Welsing P., et al. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 2009;68:668—673.
Abraham N.S., El-Serag H.B., Hartman C., et al. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment Pharmacol Ther 2007;25:913—924.
Hippisley-Cox J., Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005;330:1366.
Baron J.A., Sandler R.S., Bresalier R.S., et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 2008;372:1756—1764.